Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Contineum Therapeutics (NASDAQ:CTNM) from a sell rating to a hold rating in a research note published on Sunday morning.

Other research analysts have also issued reports about the company. Morgan Stanley increased their price objective on Contineum Therapeutics from $14.00 to $16.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Friday, July 17th. Finally, Royal Bank Of Canada upped their target price on Contineum Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.25.

Contineum Therapeutics Price Performance

Shares of CTNM opened at $17.05 on Friday. The firm has a market capitalization of $641.42 million, a PE ratio of -9.86 and a beta of 0.74. Contineum Therapeutics has a 1-year low of $8.60 and a 1-year high of $17.51. The company’s fifty day moving average price is $14.65 and its 200-day moving average price is $13.94.

Contineum Therapeutics (NASDAQ:CTNM) last released its earnings results on Thursday, July 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.05. As a group, research analysts anticipate that Contineum Therapeutics will post -1.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Contineum Therapeutics

Several large investors have recently made changes to their positions in CTNM. Strs Ohio acquired a new stake in Contineum Therapeutics during the first quarter valued at $27,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Contineum Therapeutics during the 4th quarter worth about $43,000. Qube Research & Technologies Ltd purchased a new stake in shares of Contineum Therapeutics during the 2nd quarter worth about $43,000. Marex Group plc purchased a new stake in shares of Contineum Therapeutics during the 2nd quarter worth about $45,000. Finally, Royal Bank of Canada grew its position in shares of Contineum Therapeutics by 73.5% during the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock valued at $76,000 after acquiring an additional 2,454 shares during the period.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.